Click here to go to the previous page
Maximising Value: How Tough Markets Are Reshaping the Business Models of Big Pharma and Venture Capital
Program Code:
3147
Date:
Wednesday, May 20, 2009
Time:
4:00 PM to 5:30 PM
EST
SPEAKER
(S):
Brian Atwood, MBA, Versant Ventures
Gordon Beck, Global Head, Drug Delivery, Roche
Eric De La Fortelle, F. Hoffmann-La Roche, Inc
Ian Massey, DPhil, Synosia Therapeutics
Michael Ross, PhD, SV Life Sciences
Nigel Sheail, Roche
Barbara Yanni, VP & Chief Licensing Officer , Merck & Co, Inc
Description
Debate rages as to how long the financing drought will last for initial public offerings (IPOs) of drug discovery and development companies. But one thing is certain: the longer the window remains closed, the more it is reshaping the business models of big pharma and venture capital. Hear from those at the forefront of change how current conditions are driving values of deals and acquisitions.
• Understand deal values in today's market
• Learn what represents success from a pharma and VC point of view
• Appreciate what has changed and what has stayed the same in terms of business models